The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

FARGO, N.D. (Valley News Live) - Changes are coming to the way schizophrenia is treated. The US Food and Drug Administration ...

Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

London: Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not ...

Neurocrine Biosciences has reported that its Phase II ERUDITE clinical trial of luvadaxistat did not achieve its primary endpoint in improving cognitive impairment in schizophrenia patients.

Neurocrine said it will focus its resources on late-stage development of its other schizophrenia and depression drug candidates. Shares of the company were down 2.5% in extended trading.

(Reuters) -Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not achieve ...

It’s that time of year when many of those who have Part D prescription drug coverage experience sticker shock. Here is a sample of what’s happening with my clients. Can this be right?